Market Research Logo

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Neutropenia Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Neutropenia - Overview
Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis
Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies
Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes
Chemotherapy Induced Neutropenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chemotherapy Induced Neutropenia - Products under Development by Companies
Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
Apotex, Inc.
Biogenomics Limited
Bolder Biotechnology, Inc.
Cellerant Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Dr. Reddy's Laboratories Limited
Generon (Shanghai) Corporation Ltd.
Genexine, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hospira, Inc.
Myelo Therapeutics GmbH
Octapharma AG
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
Reliance Life Sciences Pvt. Ltd.
Richter Gedeon Nyrt.
Sandoz International GmbH
UAB Profarma
USV Limited
Welichem Biotech Inc.
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eflapegrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-627 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GXG-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myelo-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WBI-2100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Neutropenia - Recent Pipeline Updates
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Featured News & Press Releases
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China
May 10, 2011: Dr Reddy’s Launches Pegfilgrastim In India Under Brand Name Peg-grafeel
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients
Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology
Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2015
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Apotex, Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Hospira, Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2015
Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H2 2015
Chemotherapy Induced Neutropenia - Dormant Projects, H2 2015
Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H2 2015
Chemotherapy Induced Neutropenia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2015
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report